cNeuro cMRI

by Combinostics Oy  · Based in Finland → — A complete AI solution to support the early detection, diagnosis, and management of major neurological disorders.
Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

cNeuro cMRI is a cloud-based AI software that provides fully automated brain MRI quantification, designed to increase throughput, enhance objectivity, and deliver high-quality reporting for improved patient care. It integrates with PACS, allowing results to be viewed within PACS or through the cNeuro browser-based viewer. The software objectively quantifies disease-specific abnormalities and patterns, reducing variability in radiological interpretation. It performs reliable and reproducible analysis of brain T1 and FLAIR MRI, including volumes of 133 cortical and subcortical regions, white-matter lesions, and additional disease-specific biomarkers. cNeuro cMRI also quantifies longitudinal changes in brain structure and lesions, aiding in the identification of subtle, disease-specific changes difficult to detect visually. The tool automates the reporting of objective, clinically meaningful data, saving time for radiologists and improving collaboration with referring clinicians through clinically focused reports for conditions like dementia, multiple sclerosis (MS), traumatic brain injury (TBI), and epilepsy. The software compares calculated volumes to a normative database of over 10,000 healthy controls, highlighting deviations from normal.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fully automated brain MRI quantification
  • Increased throughput and objectivity
  • High-quality, clinically focused reports
  • Integration with PACS
  • Browser-based viewer for results
  • Quantification of 133/135 cortical and subcortical regions (T1)
  • White-matter lesion quantification (FLAIR)
  • Quantification of longitudinal changes in brain structure and lesions
  • Disease-specific biomarkers (e.g., MTA, GCA, Fazekas scales)
  • Comparison to normative database

Use Cases

  • Early detection and differential diagnostics in Alzheimer's disease and other dementias
  • Diagnosis and management of Multiple Sclerosis (MS)
  • Diagnosis and management of Traumatic Brain Injury (TBI)
  • Diagnosis and management of Epilepsy
  • Objective assessment of atrophy and lesion load
  • Longitudinal monitoring of subtle brain changes

What Physicians Need to Know

Brain MRI Analysis
Provides fully automated quantification of brain MRI, analyzing T1 and FLAIR images. It quantifies volumes of 133-135 cortical and subcortical regions, white-matter lesions (FLAIR hyperintensities), and additional disease-specific biomarkers. The tool also quantifies longitudinal changes in brain structure and lesions, comparing results to normative reference data adjusted for age, sex, and intracranial volume. It computes MTA, GCA, and Fazekas scales, and offers vascular burden quantification.
Neurodegenerative Disease Screening
A core function, cNeuro cMRI supports the detection and monitoring of various neurological disorders including dementias (e.g., Alzheimer's disease, frontotemporal dementia, vascular dementia), multiple sclerosis (MS), Parkinson's disease, traumatic brain injury (TBI), and epilepsy. It provides objective, quantifiable insights for early detection, differential diagnosis, prediction of disease progression, and patient monitoring by comparing patient data to a large database of previously diagnosed patients.
Triage Prioritization Speed
Aims to increase throughput by reducing the time spent per image read and automates the reporting of objective, clinically meaningful data. While it enhances efficiency, the general processing time is stated as >10 minutes, indicating its primary use for comprehensive analysis rather than ultra-rapid acute stroke triage.
Mobile Notification System
The cNeuro platform, which includes cMRI, supports email notifications for key system events.
Physician Tip

Leverage cNeuro cMRI for objective and reproducible quantitative analysis of brain MRI, particularly for neurodegenerative diseases. Utilize its longitudinal analysis capabilities to track subtle changes in brain atrophy and lesions over time, crucial for monitoring disease progression and treatment response. Integrate the detailed reports and interactive viewer into clinical workflows to enhance communication with referring clinicians and improve patient management. Use the comparison to normative data for early detection and differential diagnosis. While valuable for epilepsy and TBI, remember its primary function is structural quantification, not real-time event detection.

cNeuro cMRI is a cloud-based AI software designed for integration with PACS (Picture Archiving and Communication System). Results can be viewed directly within PACS or via a dedicated browser-based viewer. It outputs PDF reports and labeled T1 and FLAIR volumes in DICOM and DICOM-PDF formats. The system can be integrated through AI marketplaces or distribution platforms, or used as a standalone web-based application. Analysis can be triggered automatically post-acquisition or on-demand. Combinostics has partnered with ConcertAI's TeraRecon for integration onto the Eureka Clinical AI platform, and Combinostics was acquired by SyntheticMR AB in early 2025, integrating cNeuro cMRI into SyntheticMR's offerings.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact vendor — N/A
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

cNeuro cMRI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on January 15, 2018 (K171328) as a Class II medical device.
Integrations
EHR Not specified
Specialties Neurology, Radiology

What the Web Says

cNeuro cMRI is an AI-powered, cloud-based software developed by Combinostics that provides automated brain MRI quantification to assist in the diagnosis and management of neurodegenerative diseases like Alzheimer's, frontotemporal dementia, vascular dementia, and multiple sclerosis. It aims to offer objective data, increase diagnostic accuracy and efficiency for radiologists, and improve communication between clinicians. The software integrates with PACS and offers browser-based viewing, providing detailed reports for radiologists, referring clinicians, and patient-oriented reports in less technical language.

Overall: Positive

Strengths

  • Provides fully automated brain MRI quantification, increasing throughput and objectivity.
  • Aids in early detection, differential diagnosis, and prediction of disease progression for various neurological disorders.
  • Reduces variability in radiological interpretation and increases accuracy and sensitivity.
  • Improves collaboration and communication between radiologists and referring clinicians through high-quality, clinically focused reports.
  • Offers interactive image review, allowing comparison of multiple timepoints and assessment of segmentation results.
  • Generates patient-oriented reports in easy-to-understand language.

Limitations

  • No specific cons were found in the provided search results from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra.
  • Some general Reddit discussions about MRIs for neurological symptoms indicate that standard MRIs sometimes don't reveal issues despite severe symptoms, but this is not specific to cNeuro cMRI.

Based on reviews from: Combinostics: Faster diagnoses with artificial intelligence - VTT Technical Research Centre, Combinostics | AI Technology to Support Early Diagnosis, cNeuro cMRI - Combinostics, Advanced MRI Brain Health Assessment | cNeuro Cominostics - Bionicc Body Screening, Deal Brings AI-powered MRI to Care of Patients With MS, Brain Disorders, Combinostics - Medical Technology | Issue 36 | February 2021, Overview of cNeuro cMRI - YouTube

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate cNeuro cMRI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Combinostics
Combinostics' cDSI and cMRI Applications, Part of the cNeuro Platform, Receive EC-certification Under the EU's Medical Device Regulation (MDR)
Combinostics announced that its cDSI and cMRI applications, part of the cNeuro platform, have received EC-certification under the European Union's Medical Device Regulation (MDR), ensuring compliance with new regulatory frameworks for medical devices in Europe.
2022-06
PR Newswire
Combinostics Partnership with ConcertAI's TeraRecon adds AI-based Evaluations for Neurodegenerative Disease and Multiple Sclerosis to Eureka Clinical AI
Combinostics partnered with ConcertAI's TeraRecon to integrate cNeuro cMRI into the Eureka Clinical AI platform, providing AI-based evaluations for neurodegenerative diseases and multiple sclerosis to approximately 1900 health sites globally.
2023-04
Combinostics
Combinostics Launches Latest Version of Its cNeuro Platform
Combinostics released version 2.1.0 of its cNeuro platform, which includes the cDSI and cMRI applications, offering new reports, biomarkers, and the industry-first Dementia Differential Analysis report.
2022-06
PMC (via Neurology)
Automated magnetic resonance imaging quantification of cerebral parenchymal and ventricular volume following subarachnoid hemorrhage: associations with cognition
This peer-reviewed article discusses the use of cNeuro cMRI as a novel automatic clinical MRI quantification tool for volumetric analysis of brain structures following subarachnoid hemorrhage, validated in multiple sclerosis and dementia.
2024-01
AllMind AI News
Regulatory Approval for ARIA Monitoring Strengthens SyntheticMR's Position with a Broader Neuroimaging Offering | AllMind AI News
SyntheticMR, following its early-2025 acquisition of Combinostics, has integrated cNeuro cMRI into its portfolio and gained European regulatory clearance for automated ARIA detection to monitor side effects of anti-amyloid Alzheimer's therapies.
2025-03
AuntMinnie.com
Combinostics gets FDA clearance for quantification software
Combinostics received FDA 510(k) clearance for its cNeuro cMRI quantification software, enabling objective measurements of brain atrophy and white matter hyperintensities for neurodegenerative diseases.
2018-01
Combinostics
Combinostics and Siemens Healthineers partner to distribute cNeuro cMRI application
Combinostics and Siemens Healthineers announced a partnership to distribute Combinostics' cNeuro cMRI application through the Siemens Healthineers Digital Ecosystem, providing clinicians with objective measurements of brain atrophy.
2018-03
British Journal of Radiology
Artificial intelligence in neuroradiology: a review of Food and Drug Administration-regulated algorithms
This review of FDA-regulated AI algorithms in neuroradiology lists cNeuro cMRI by Combinostics Oy as an FDA-cleared device for volumetric measurements of brain structures and FLAIR white matter hyperintensities, cleared in January 2018.
2026-05

Videos

Product demos, reviews, and walkthroughs for cNeuro cMRI.

View all on YouTube

Frequently Asked Questions

cNeuro cMRI is a cloud-based AI software that integrates with PACS, allowing results to be viewed within your standard reading environment or via a browser-based viewer. It provides fully automated brain MRI quantification, offering objective data on brain structure volumes and white matter abnormalities, which can increase accuracy, sensitivity, and reduce reading time for neurological disorder diagnosis and management.
cNeuro cMRI is CE marked (MDR Class IIa) and FDA 510(k) cleared for clinical use, demonstrating its compliance with stringent medical device regulations. Combinostics ensures data privacy and security through SSL encryption for all data transfers, and stored data are anonymized and encrypted.
While cNeuro cMRI provides objective quantitative data, it is an adjunctive tool and should not replace comprehensive clinical judgment. The accuracy of its analysis relies on the quality of input MRI images, and interpretation should always be done in the context of the patient's full clinical picture.
Several other AI-powered tools offer automated brain MRI quantification, including NeuroQuant, Quantib ND, QUIBIM Precision, and Pixyl.Neuro. cNeuro cMRI differentiates itself by providing quantification of 133 brain structures, disease-specific biomarkers, and comprehensive reports for various neurological disorders, often as part of the broader cNeuro platform that integrates with cDSI for clinical decision support.
cNeuro cMRI is typically offered under a subscription-based pricing model, with costs often determined by the number of analyses performed. Specific pricing details usually require direct consultation with Combinostics to align with the unique needs and volume of a practice or hospital.
Combinostics provides peer-reviewed publications validating cNeuro cMRI's methodology for automatically computing rating scales and its utility in differential diagnosis of neurodegenerative diseases. The software compares patient data to a normative database of over 10,000 healthy controls, supporting its quantitative assessments.
Combinostics offers demonstrations of cNeuro cMRI, and the platform is designed for easy integration and use within standard reading environments. While specific training programs aren't detailed, the company emphasizes user-friendly reporting and browser-based viewing, suggesting readily accessible support and resources.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.